The pieces will be hard-faced Beijing Tongren Tong.

Pharmaceutical Network July 30th, 17 years after the listing, the film (SH:600436) finally has a new action on the merger and acquisition.
July 25 and 27, the film issued two announcements, said that it will have its own capital of 44.4759 million yuan, to Longyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Longyu Pharmaceuticals") to invest in the holding of shares, and obtain edified 51% of the shares of Longyu Pharmaceuticals.
at present, Longyu Pharmaceuticals has completed the change of equity.
, however, the acquisition did not set off much of a splash in the capital markets. Since
25, the share price of the stock has been declining steadily, until the 28th only recovered.
as of today's close, the company closed at 194.38 yuan, up 1.27 percent, with a market value of 117.273 billion yuan.
Beijing Dingchen Pharmaceutical Management Consulting Center founder Shi Lichen told reporters on July 27, "The acquisition of Longzi Pharmaceuticals will directly obtain a number of classic Chinese medicine, further enrich the product pipeline, and alleviate the long-term dependence of the tablet sac on liver disease drugs."
" on the same day, the film said in an interview with reporters, "the company and Longyu Pharmaceuticals are still in the stage of business integration, for all kinds of Chinese and Western pharmaceutical products are currently under review."
" tablets won more than a hundred Chinese and Western pharmaceutical products in the pharmaceutical circle rarely mentioned small pharmaceutical companies why let the tablets throw a thousand dollars? Speaking of the reasons for the acquisition, the film made it clear in both announcements that the acquisition of Dragon's Pharmaceuticals is to improve the industrial layout, enrich the product pipeline.
However, after the announcement of the acquisition, some investors are not optimistic that there is a greater operational risk to Longyu Pharmaceuticals.
Longyu Pharmaceuticals was established in August 2005, registered capital of 100 million yuan, the main business scope for the production of tablets, capsules, granules, combined agents, etc., with more than 115 Chinese and Western drug approval number.
in addition to traditional Chinese medicine, the main income of longepine pharmaceutical industry comes from acetyl salicylic acid tablets, compound ammonia phenol hylon, depain tablets and other popular drugs, but the homogenization of such products serious, easy to replace, there is not much competitive advantage. in addition,
, because the main sales channels of Theron Pharmaceuticals are in Heilongjiang Province, partly concentrated in Qiqihar City, drug sales channels and scale are also very limited.
in Shi Lichen's view, the film can take the dragon medicine industry as a production base of products, in the Northeast outside the construction of operations and sales system.
However, from the performance point of view, the situation of Longyu Pharmaceuticals is not optimistic, 2019 to achieve revenue of 2204.87 million yuan, net profit of 654.68 million yuan, as of the end of 2019, Longyu Pharmaceuticals (unaudited) total assets of 43.7627 million yuan, net assets of 1.4151 million yuan.
for the current operation of the dragon medicine industry and the integration risks faced by the film, the film aberdeen side in response to the times financial said, "At present, the integration of The Dragon Pharmaceutical industry is still in the initial stage, the company's management team will do the corresponding assessment."
the implementation of the integration planning and product channel layout and other issues, but also with the two operating teams and downstream distributors, buyers further discussions.
" or will grab Beijing Tongrentang "cake" pieces to buy The Dragon Pharmaceutical sin is that the latter owns Angong oxen yellow pills, West Yellow Pills and other high-value Traditional Chinese medicine.
also told reporters that after the acquisition will focus on the development of the two drugs, gong oxen yellow pills and west yellow pills.
reporters query financial report data found that Angong oxen yellow pills is an annual sales of more than 1 billion yuan of cerebrovascular disease drugs, in recent years the growth rate has remained above 20%, 2019 sales of more than 2.4 billion yuan.
at present, the state-approved, can use natural musk to produce Angong oxen yellow pills only five enterprises, including Longyu Pharmaceuticals, Beijing Tongren Tang, Shanxi Guangyuyuan, central pharmaceutical industry Darentang and Nanjing TongrenTang.
, Beijing TongrenTang is a family.
's Beijing Tongrentang shares Tongrentang Pharmaceuticals and Beijing Tongrentang Technology Pharmaceuticals, 2019 Angong Cattle Yellow Pill total sales of 1.8 billion yuan, up 35% YoY, the two pharmaceutical companies combined market share of up to 74.5%.
because the ingredients contain ox yellow, musk, rhino horn concentrated powder and other valuable herbs, the price of anpalace oxen yellow pills is not friendly.
the current market price of 500-800 yuan / grain, gross margin as high as 60%-80%.
taking into account the huge profits of Angong oxen pills and huge market, coupled with the film is owned by the oxen, musk and other raw material resources, after the completion of the acquisition into the Angong bull yellow pill market has no suspense.
said it will cooperate substantially with Longyu Pharmaceuticals in Angong's oxen martens, with the expected annual production of 20,000 Maru Angong oxan yellow pills.
this also means that the leading Beijing TongrenTang will be a strong competitor.
the first quarter of this year, Angong ox encarnos also entered the "new crown virus infection of pneumonia diagnosis and treatment program" recommended medication, however, the pharmaceutical industry senior practitioners, pharmacology Doctor Tan Yaxuan told reporters on July 27, Angong oxen yellow pills for the new crown patients treatment effect is not amazing.
that's why, an palace oxen yellow pills in the new crown of effective medicine speculation did not stir up too much water flowers.
the west yellow pill, which has received the attention of the tablets, is a broad-spectrum anti-cancer drug.
in Tan Ya-tung's view, "The west yellow pills and the tablets have the same ingredients, including expensive oxen and musk, the company may have the intention of merging the same items."
" also has the industry to the Times Financial said, Angong oxen yellow pills and West Yellow Pills are expected to become the next two sharp weapons after the series of hepatology drugs in the pasika.
the "one wing" strategy imbalance at present, the main products of the tablets cover liver disease drugs, cardiovascular drugs, cold drugs, diabetes drugs and many other fields, its core products for the film, but also the company's main source of revenue.
however, affected by the shortage of natural musk of raw materials, since 2005, the price of the film's sage products has soared, after 14 price increases, from 130 yuan / grain to 590 yuan / grain.
industry forecasts, the price of the film may climb to 1000 yuan / grain.
despite the constant price increases, as raw material prices rose, the gross profit of the company did not rise or fall, from 47.01% in 2015 to 44.24% in 2019.
under pressure, since 2014 began to implement the "one wing" strategy, with the film as the body, the development of day-to-day and health care products two wings.
multi-category strategy does not seem to be in accordance with the original direction of development, the japanese plate than the core pharmaceutical sector growth is better.
pieces told reporters, "The company has been to drugs as the core, but for the layout of the Japanese business will not relax."
" on July 14 released the 2020 half-year results report shows that the first half of the year is expected to achieve revenue of about 3.246 billion yuan, up 12.15 percent year-on-year, and net profit of about 861 million yuan, up 15.32 percent year-on-year.
's performance growth is mainly due to the company's core products, the company's core products, the holding subsidiary Of fujian Taipa Yi Yi E-commerce Co., Ltd. and the holding subsidiary of Fujian Sina-Yi Cosmetics Co., Ltd. sales growth.
is understood that the first half of this year, the production revenue of the daily products of the film, more than 330 million yuan, up 50% year-on-year.
according to officials, the sales target for the full year 2020 is 600 million yuan.
in Shi Lichen's view, affected by market factors, Japanese chemical ization has become an important direction for Chinese medicine enterprises to expand their product lines, many Chinese medicine enterprises can only maintain development through "diversification".
reporters note that a number of established Chinese medicine enterprises, including Yunnan White Medicine (SZ:000538), Baiyunshan (SH:600332/HK:00874) and Ma Yinglong (SH:600993), have entered the Japanese chemical market.
" cosmetics and daily chemical business in the product marketing level is still lacking, the need to strengthen the brand of japanese products in order to be more popular with young consumers today.
," Shrichen said.
.